Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.
• Treatment for Advanced Melanoma: New Drugs, New Opportunities, New Challenges
• The Past, Present, and Future of Melanoma Therapy

This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.
• Lessons From Considering the Cancer Landscape
• Adapting to the Brave New World of Lung Cancer Treatment

Recently published research questions the need for the advised restriction against the use of soyfoods by women with a history of breast cancer.
• Soyfood Consumption in Breast Cancer Survivors: Don't Overstate the Facts!
• A Fitting Prescription for All: Whole Soyfoods as Part of a Varied Plant-Based Diet

Ongoing studies are attempting to understand the reasons that tumor cells engage in aerobic glycolysis in lieu of oxidative phosphorylation. In this review, we discuss known benefits to tumor cells from this metabolic switch, and we highlight key enzymes that play a role in aerobic glycolysis. We also describe novel therapeutic options targeting glucose metabolism.
• Metabolic Synthetic Lethality
• Finding the Right Target(s) in the Context of Tumor Heterogeneity, Evolution, and Metabolic Plasticity